Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is...

Area of Science:

• Immunology
• Autoimmune Diseases
• Biomarker Discovery

Background:

• Programmed cell death-1 protein (PD-1) and its ligands (PD-L1, PD-L2) regulate T cell signaling and immune homeostasis.
• PD-1 and PD-L1 are implicated in autoimmune diseases, but PD-L2's role, particularly in systemic lupus erythematosus (SLE), is understudied.
• Understanding PD-L2's function in SLE is crucial for developing new diagnostic and therapeutic strategies.

Purpose of the Study:

• To investigate changes in membrane-bound PD-L2 expression on peripheral blood mononuclear cells and soluble PD-L2 (sPD-L2) in patients with SLE.
• To explore the association between PD-L2 expression levels and SLE disease activity, including clinical manifestations and laboratory parameters.
• To evaluate the potential of PD-L2 as a biomarker for SLE pathogenesis.

Main Methods:

• Analysis of membrane-bound PD-L2 expression on monocytes from SLE patients and healthy controls.
• Quantification of serum soluble PD-L2 (sPD-L2) levels in SLE patients and healthy individuals.
• Correlation analysis between PD-L2 levels, SLE disease activity indices, and complement components (C3/C4).

Main Results:

• Significantly higher membrane-bound PD-L2 expression on monocytes was observed in SLE patients compared to healthy subjects.
• Significantly lower serum sPD-L2 levels were found in SLE patients relative to healthy controls.
• Low sPD-L2 secretion was associated with active SLE, lupus nephritis, joint pain, and oral ulcers, and positively correlated with C3/C4 levels.

Conclusions:

• PD-L2 expression patterns are altered in SLE patients.
• Reduced sPD-L2 levels may indicate active disease and are linked to complement component levels in SLE.
• PD-L2 warrants further investigation as a potential biomarker for SLE pathogenesis and activity.